<DOC>
	<DOCNO>NCT02109328</DOCNO>
	<brief_summary>Background : Progress develop new effective therapy advance relapse urothelial cancer stagnant last decade paradigm shift desperately need . Aurora kinase-A overexpression previously describe bladder cancer spindle checkpoint dysregulation common feature human urothelial carcinoma ( UC ) . Alisertib ( Millennium Inc. ) orally available , selective small molecule inhibitor Aurora A kinase . Single agent combination treatment MLN8237 either paclitaxel ( TXL ) gemcitabine synergistically reduce UC cell viability compare either drug alone . Hence , sequential application MLN8237 TXL warrant clinical investigation . Phase 1 trial single agent combination TXL define recommended dos phase 2 trial . Methods : A multistep approach adopt Phase 2 trial . A single-group run-in phase conduct first Alisertib 50 mg orally BID 7 day , follow 14d rest disease progression . In case activity , confirmatory randomize ( 1:1 ) trial weekly TXL plus either Alisertib Placebo follow , incorporate efficacy futility boundary early stop . In single-blind design , TXL give day 1,8,15 q4wks dose 60 mg/m2 alisertib 80 mg/m2 placebo . Alisertib dose 40 mg BID day 1-3 , 8-10 15-17 , q4wks . In single-arm phase , primary endpoint ( EP ) Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 response-rate . 20 pt accrue , â‰¥3 response require ( 10 % type I 20 % type II error constraint ) . An accrual 110 pt foreseen randomized phase . Primary EP : progression-free survival ( PFS ) , assume improvement PFS median 2.5 month ( H0 ) median 4.5 month ( H1 ) ( 44 % hazard rate reduction , 10 % drop rate ) . Eligibility include diagnosis metastatic UC failure 1-2 CT regimen ( single-arm ) 1 prior CT ( randomized phase ) . A relapse within 6 month peri-operative CT count 1 line . Computed tomography PET do every 2 cycle ( 2 month ) . Additional pharmacodynamic translational analysis plan pre- post- blood tissue sample .</brief_summary>
	<brief_title>Alisertib Chemotherapy-pretreated Urothelial Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Histologically confirm diagnosis transitional cell tumor bladder urothelium . Locally advanced ( T3b , N0 ; every T , N+ ) metastatic disease . Failure max.2 chemotherapy regimens metastatic disease ( least 1 include platinum compound ) . Neoadjuvant/adjuvant therapy consider relapse occur within 6 month last cycle chemotherapy . Failure meet eligibility requirement . Serious medical psychiatric illness likely interfere participation clinical study . Major comorbidities specify protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Bladder cancer</keyword>
	<keyword>Urothelial cancer</keyword>
	<keyword>Alisertib</keyword>
	<keyword>Phase 2</keyword>
	<keyword>Advanced disease</keyword>
</DOC>